DOCSLIB.ORG

Inhibitory Effects of Trifluoperazine and Chlorpromazine, Calmodulin Inhibitor, on Autoregulation of Renal Blood Flow

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Inhibitory Effects of Trifluoperazine and Chlorpromazine, Calmodulin Inhibitor, on Autoregulation of Renal Blood Flow Inhibitory Effects of Trifluoperazine and Chlorpromazine, Calmodulin Inhibitor, on Autoregulation of Renal Blood Flow Nobuyuki OGAWA, Syunji YOKOTA and Hiroshi ONO Departmentof Pharmacologyand Toxicology,Hatano ResearchInstitute, Food and DrugSafety Center,729-5, Ochiai,Hadano, Kanagawa257, Japan Accepted January 6, 1987 Abstract-An intra-arterial infusion of a calmodulin inhibitor trifluoperazine (3 mg/min) or chlorpromazine (5 mg/min) caused obvious inhibition of autoregu lation of renal blood flow in dogs. Simultaneous infusion of CaCl2 (30 mg/min) or Ca channel activator BAY K 8644 (5 fig/min) with these calmodulin inhibitors reduced renal blood flow, but could not block the inhibitory activity of calmodulin inhibitors on the autoregulation. The present experiment shows the contribution of the Ca-calmodulin system to the mechanism of autoregulation of renal blood flow. The renal blood flow is maintained infusion of a calmodulin inhibitor, tri remarkably constant by autoregulation over fluoperazine or chlorpromazine (7) in the a wide range of perfusion pressures. As for kidney of anesthetized dog. Furthermore, the the mechanism, presently it is accepted that effect of simultaneous infusion of CaCl2 or the principal process is the myogenic response BAY K 8644 with these calmodulin inhibitors of the vascular smooth muscle automatically was also examined. adjusting tone to the change of perfusion Ten mongrel dogs of either sex, weighing pressure. We have demonstrated a chain of 12-20 kg, were anesthetized with a evidence that autoregulation of renal blood chloralose (40 mg/kg) and urethane (400 flow is directly dependent on transmembrane mg/kg), intravenously, preceded by sedation influx of Ca21 through Ca channels; the with morphine hydrochloride (2 mg/kg, s.c.). abolition of autoregulation caused by The left renal artery was exposed retroperi verapamil, nifedipine and diltiazem was toneally, cannulated and perfused with blood antagonized by CaCl2 (1, 2) or BAY K 8644, conducted from the carotid artery by means a Ca channel activator (3, 4). Also we have of a Harvard peristaltic pump (Model 1215). reported that EDTA abolished renal auto An initial dose of 500 U/kg of sodium heparin regulation, and this effect of EDTA was was given as anticoagulant. Perfusion counteracted by simultaneous infusion of pressure was regulated by the use of CaCl2, but not by that of BAY K 8644 (4). Starling's pneumatic resistance through which Several investigators have shown that excess blood was conducted to the left the Ca-calmodulin system is involved in the jugular vein. A desired level of perfusion vascular smooth muscle activity (5, 6). pressure was obtained by changing the Therefore, the mechanism of renal blood flow pressure of the pneumatic resistance. autoregulation performed by the myogenic Perfusion pressure and systemic blood response, presumably activated by the Ca2+ pressure in the femoral artery were measured influx through Ca channels induced by the with an electric manometer (transducer: change of perfusion pressure may be de Statham P23Db and carrier amplifiers: San pendent on calmodulin. ei 1206B). Renal blood flow was measured The present experiment was designed to by an electromagnetic flowmeter (Narco RT test the above hypothesis. The pressure-flow 500). These parameters were recorded on an relation was examined before and during ink-writing oscillograph (San-ei 8S-53). Smaller doses of a-chloralose and urethane presented as means+S.E. were supplemented when necessary, and Control observations show a complete sodium heparin was supplemented con autoregulation which maintained renal blood stantly by 100 U/kg/hr. A drug solution was flow constant and an ARI value less than infused into a rubber tube connected close 0.1 in the range of 120-200 mmHg. Partial to the shank of the renal arterial cannula by autoregulation was also shown between 100 the aid of an infusion pump (Harvard Model and 120 mmHg (Figs. 1 and 2). 901). The intra-arterial infusion of trifluoperazine The experimental protocol consisted of 4 increased renal blood flow significantly at a periods. The first period was for the control, perfusion pressure above 120 mmHg and and the perfusion pressure was changed between 60 and 200 mmHg to examine the autoregulatory response to the renal vasculature. Then, in the second period, trifluoperazine (3 mg/min) or chlorpromazine (5 mg/min) was infused into the renal artery, and autoregulation was examined again. In the third period, simultaneous infusion of CaCI2 (30 mg/min) with tri fluoperazine or chlorpromazine was per formed, and the autoregulation was examined. In the forth period, BAY K 8644 (5 /cg/min) was infused with trifluoperazine or chlor promazine. The changing maneuver of the perfusion pressure was performed 10 min after the onset of each infusion. Doses of trifluoperazine and chlorpromazine were determined to cause adequate inhibition of the renal autoregulation by a preliminary search. BAY K 8644 was donated by Bayer AG. Trifluoperazine dihydrochloride and chlor promazine hydrochloride were purchased from Funakoshi and Wako, respectively. BAY K 8644 was dissolved in 99.5% ethanol to a concentration of 1 mg/ml. This stock solution was diluted to a desired concen tration with 0.9% saline. The dose of drugs is expressed as the weight of the base. The efficiency index of autoregulation (ARI) was calculated according to the Fig. 1. Effects of trifluoperazine-CaCl2 and -BAY K formula of Semple and DeWardener (8) : 8644 on the relationship of renal blood flow to renal perfusion pressure (upper panel) and the autoregula ARI (RBF2-RBF1)/RBF1 (P tory indexes of renal blood flow (lower panel) (n=5). RA2-PRA1)/PRA1 Symbols show means and vertical bars show S.E. where the renal blood flow changes RBF2 0-0: control pressure-flow, •-•-S: that dur from the initial value of RBF1 when renal ing infusion of 3 mg/min of trifluoperazine, A-••-A: that during simultaneous infusion of CaC12 (30 mg/ perfusion pressure is altered to PRA2from the min) with trifluoperazine, A-•••-A: that during initial value of PRA1. simultaneous infusion of BAY K 8644 (5 jig/min) Differences of means were analyzed with trifluoperazine. *shows a significant difference using the paired t-test and were considered from the corresponding value of the control (P< significant when P<0.05. Data will be 0.05). 8644 (5 ug/min) with trifluoperazine decreased renal blood flow and shifted the pressure-flow curve parallel to the right, but the autoregulation was still impaired. Con sequently, the blood flow rate was sig nificantly lower than the control rate at perfusion pressures below 120 mmHg (Fig. 1). The infusion of chlorpromazine (5 mg/ min) also caused a pressure-dependence of renal blood flow in all perfusion pressure ranges; i.e., chlorpromazine impaired the autoregulation (Fig. 2). ARI between 120 and 200 mmHg was higher than that of the control period (Fig. 2). Simultaneous infusion of CaCI2 (30 mg/min) or BAY K 8644 (5 fig/min) with chlorpromazine decreased renal blood flow to a level significantly lower than that of the control for perfusion pressures below 120 mmHg (Fig. 2). ARI during simultaneous infusion of CaCI2 or BAY K 8644 with chlorpromazine was even higher than during the infusion of chlor promazine alone (Fig. 2). Calmodulin has been considered to be an important regulator in the mechanism of vascular smooth muscle contraction (5, 6). Calmodulin inhibitor W-7 (5) produced relaxation of rabbit aortic strips with various agonist, and these agonist-induced con tractions were inhibited in a noncompetitive Fig. 2. Effects of chlorpromazine-CaCl2 and -BAY K fashion. W-7 also shifted the dose-response 8644 on the relationship of renal blood flow to renal curve for CaCI2 both rightward and down perfusion pressure (upper panel),and the autoregula ward (5, 6). This inhibitory effect of W-7 was tory indexes of renal blood flow (lower panel) (n=5). obviously different from those of Ca 0-0: control pressure-flow, •-•-6: that during antagonists such as verapamil and nifedipine infusion of 5 mg/min of chlorpromazine, A -A: (6). Thus, these observations suggested that during simultaneous infusion of CaC12 (30 that calmodulin contributed to a common mg/min) with chlorpromazine, A-•••-A: that during process in the course of smooth muscle simultaneous infusion of BAY K 8644 (5 pg/min) contraction. with chlorpromazine. *shows a significant differ Previously, one of the authors reported ence from the corresponding value of the control that verapamil and nifedipine inhibited renal (P<0.05). blood flow autoregulation, but these inhibitory effects were antagonized by caused a pressure-dependence of renal simultaneous infusion of CaCl2 with Ca blood flow and ARI higher than that of the antagonists in dog kidney (1). Furthermore, control period in all perfusion pressure ranges our recent study showed that the inhibitory (Fig. 1). Mean systemic blood pressure effects of verapamil and nifedipine in renal decreased significantly from 116±6 to 110±4 autoregulation were antagonized by simul mmHg (P<0.05) at 10 min after the start of taneous infusion of the Ca channel activator trifluoperazine infusion. Simultaneous BAY K 8644 (3, 4). Therefore, it is considered infusion of CaCl2 (30 mg/min) or BAY K that the mechanism establishing auto regulatory vascular response involves, at 2 Ogawa, N. and Ono, H.: Different effects of least partly, the process of Ca2+ entry through various vasodilators on autoregulation of renal Ca channels over changes of perfusion blood flow in anesthetized dogs. Japan. J. Pharmacol. 41, 299-306 (1986) pressure. 3 Ogawa, N. and Ono, H.: Different effects of The present study showed that calmodulin noradrenaline, angiotensin II and BAY K 8644 inhibitor, such as trifluoperazine and on the abolition of autoregulation of renal blood chlorpromazine, abolished renal blood flow flow by verapamil. Naunyn Schmiedebergs Arch. autoregulation. Kanamori et al.
Load more

Recommended publications
  • Schizophrenia Care Guide
    August 2015 CCHCS/DHCS Care Guide: Schizophrenia SUMMARY DECISION SUPPORT PATIENT EDUCATION/SELF MANAGEMENT GOALS ALERTS Minimize frequency and severity of psychotic episodes Suicidal ideation or gestures Encourage medication adherence Abnormal movements Manage medication side effects Delusions Monitor as clinically appropriate Neuroleptic Malignant Syndrome Danger to self or others DIAGNOSTIC CRITERIA/EVALUATION (PER DSM V) 1. Rule out delirium or other medical illnesses mimicking schizophrenia (see page 5), medications or drugs of abuse causing psychosis (see page 6), other mental illness causes of psychosis, e.g., Bipolar Mania or Depression, Major Depression, PTSD, borderline personality disorder (see page 4). Ideas in patients (even odd ideas) that we disagree with can be learned and are therefore not necessarily signs of schizophrenia. Schizophrenia is a world-wide phenomenon that can occur in cultures with widely differing ideas. 2. Diagnosis is made based on the following: (Criteria A and B must be met) A. Two of the following symptoms/signs must be present over much of at least one month (unless treated), with a significant impact on social or occupational functioning, over at least a 6-month period of time: Delusions, Hallucinations, Disorganized Speech, Negative symptoms (social withdrawal, poverty of thought, etc.), severely disorganized or catatonic behavior. B. At least one of the symptoms/signs should be Delusions, Hallucinations, or Disorganized Speech. TREATMENT OPTIONS MEDICATIONS Informed consent for psychotropic
    [Show full text]
  • Trifluoperazine 1Mg/5Ml Syrup Can Trifluoperazine 1Mg/5Ml Syrup Have Effects on Muscle Control
    • Rarely patients may develop Neuroleptic Malignant Syndrome. This causes a high temperature, rigid muscles, drowsiness, occasional loss of consciousness, and requires emergency admission to hospital for treatment. PATIENT INFORMATION LEAFLET • If you have chest pain (angina) and your pain is getting worse. • Very occasionally, medicines such as Trifluoperazine 1mg/5ml Syrup can Trifluoperazine 1mg/5ml Syrup have effects on muscle control. If this happens, symptoms can include slurred speech, odd movements of the face, particularly of the tongue, eyes, head or neck (such as twisting of the neck which causes an Read all of this leaflet carefully before you start taking this medicine. unnatural positioning of the head, rigid muscles, tremors or restlessness Keep this leaflet. You may need to read it again. and difficulty in sitting still). Some patients (especially on high doses of If you have any further questions, ask your doctor or pharmacist. this medicine) experience problems with muscle control which may This medicine has been prescribed for you. Do not pass it on to others. It continue for years. Such patients may experience constant chewing or may harm them, even if their symptoms are the same as yours. tongue movements or other gentle movements of the neck, head or trunk. If any of the side effects become serious, or if you notice any side effects Uncontrollable movements of the arms and legs have also been reported not listed in this leaflet, please tell your doctor or pharmacist. in these patients. In this leaflet: • Occasionally, some patients have complained of feeling slowed down, 1. What Trifluoperazine 1mg/5ml Syrup is and what it is used for whilst • Rarely, jaundice (yellowing of skin and whites of eyes), eye problems, 2.
    [Show full text]
  • Opipramol and Trifluoperazine in the Treatment of Anxiety and Tension
    A COMPARATIVE STUDY OF TWO ANTIHISTAMINES 395 In table VI are given the results of a question directed at discovering how effective the preferred treatment was compared to any other antihistamine used. Fifteen patients only were able to give this information but the results are interesting. Discussion TABLE VI The design of this study was very simple as COMPARISON WITH PREVIOUSLY USED ANTIHISTAMINE such studies must be if they are to be completed under the conditions of a busy general practice. In a condition such as hay fever where anti- Worse As good Better Total histamines are known to be etfective and where fairly rapid symptomatic relief is needed by the 2 4 9 15* patient, we did not feel justified in including a placebo. The results of the study seem fairly *In the majority of patients the previously used clear-cut that if patients are offered the choice antihistamine was the chemically related chlor- of a plain form of this antihistamine or a long- pheniramine maleate B.P. acting form more will choose the latter. Ofthose that do so, however, only about a third find a single tablet at night completely effective, the remainder have to take one further tablet during the day. Both forms of antihistamine are effective and where a retrospective comparison can be made this effectiveness is considered greater or equal to that of previously administered anti-histamines. Summary A simple comparative study under general-practice conditions of two formulations of pheniramine is described. Sixty-one per cent of patients preferred the long-acting form of this antihistamine.
    [Show full text]
  • Clomipramine Suppresses ACE2-Mediated SARS-Cov-2 Entry
    bioRxiv preprint doi: https://doi.org/10.1101/2021.03.13.435221; this version posted March 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Clomipramine suppresses ACE2-mediated SARS-CoV-2 entry Yuri Kato1, Shigeru Yamada2, Kazuhiro Nishiyama1, Ayano Satsuka2, Suyong Re3, Daiki Tomokiyo1, Jae Man Lee4, Tomohiro Tanaka5, Akiyuki Nishimura5, Kenzo Yonemitsu6, Hiroshi Asakura6, Yuko Ibuki7, Yumiko Imai8, Noriho Kamiya9,10, Kenji Mizuguchi3,11, Takahiro Kusakabe12, Yasunari Kanda2*, and Motohiro Nishida1,5*,# 1 Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka 812-8582, Japan, 2 Division of Pharmacology, National Institute of Health Sciences (NIHS), Kanagawa, 210-9501, Japan 3 Artificial Intelligence Center for Health and Biomedical Research (ArCHER), National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibaraki, Osaka, 567-0085, Japan 4 Laboratory of Creative Science for Insect Industries, Faculty of Agriculture, Kyushu University, Motooka 744, Nishi-ku, Fukuoka, 819-0395, Japan 5 National Institute for Physiological Sciences & Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences, Okazaki, 444-8787, Japan 6 Division of Biomedical Food Research, National Institute of Health Sciences (NIHS), Kanagawa, 210-9501, Japan 7 Graduate Division of Nutritional and Environmental Sciences, University of Shizuoka, 52-1 Yada, Shizuoka 422-8526, Japan bioRxiv preprint doi: https://doi.org/10.1101/2021.03.13.435221; this version posted March 14, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved.
    [Show full text]
  • 3,2,4 Tricyclic Antidepressants and the Risk of Congenital Malformation
    Tricyclic antidepressants and the risk of congenital malformations CONFIDENTIAL Medicines Adverse Reactions Committee Meeting date 3/12/2020 Agenda item 3.2.4 Title Tricyclic antidepressants and the risk of congenital malformations Submitted by Medsafe Pharmacovigilance Paper type For advice Team Active ingredient Product name Sponsor Amitriptyline Arrow-Amitriptyline Film coated tablet, 10 mg, 25 Teva Pharm (NZ) Ltd mg & 50 mg Amirol Film coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Clomipramine Apo-Clomipramine Film coated tablet, 10 mg & Apotex NZ Ltd 25 mg Anafranil Tablet, 10 mg Section 29 Dosulepin Dosulepin Mylan Film coated tablet, 75 mg Mylan New Zealand Ltd Dosulepin Mylan Capsule, 25 mg Section 29 Doxepin Anten 50 Capsule, 50 mg Mylan New Zealand Ltd Imipramine Tofranil Coated tablet, 10 mg & 25 mg AFT Pharmaceuticals Ltd Nortriptyline Norpress Tablet, 10 mg & 25 mg Mylan New Zealand Ltd PHARMAC funding Product highlighted in bold above are funded on the Community Schedule. Two products (shown in italics) are funded but only available under Section 29 of the Medicines Act (ie, the products have not been approved by Medsafe). Previous MARC In utero exposure to serotonin reuptake inhibitors and risk of congenital meetings abnormalities 141st meeting March 2010 International action None Prescriber Update The use of antidepressants in pregnancy September 2010 Classification Prescription medicine Usage data The following pregnancy usage data for 2019 was obtained from the National Collections using the Pharmaceutical Dispensing in Pregnancy application in Qlik. The table shows the total number of dispensings, repeat dispensings and number of pregnancies exposed during first trimester (defined as 30 days prior to the estimated pregnancy start date to week 13) for pregnancies that ended in 2019.
    [Show full text]
  • Louisiana Fee-For-Service Medicaid Antipsychotics
    Louisiana Fee-for-Service Medicaid Antipsychotics The Louisiana Uniform Prescription Drug Prior Authorization Form should be utilized to request: Authorization for non-preferred agents for recipients 6 years of age and older; AND Authorization for all preferred and non-preferred agents for recipients younger than 6 years of age; AND Authorization to exceed maximum daily dose/quantity limit for all ages. See full prescribing information for individual agents for details on the information below: *These agents have Black Box Warnings †These agents are subject to Risk Evaluation and Mitigation Strategy (REMS) under FDA safety regulations ‡ For long-acting injectable agents, it is required that the previous 60-day period of pharmacy claims show one of the following: Established tolerance to the oral formulation (as evidenced by a paid pharmacy claim for the oral formulation); OR Established therapy with the requested injectable agent (as evidenced by a paid pharmacy claim for the requested injectable agent) NOTE: Diagnosis code requirements apply to both preferred and non-preferred agents (see Table 1). Maximum daily dose edits (see Table 2), quantity limits (see Table 3), and other requirements at Point-of-Sale for select agents in this category may apply to both preferred and non-preferred agents. For additional information, see http://www.lamedicaid.com/provweb1/Pharmacy/pharmacyindex.htm. Oral Antipsychotics – Generic Name (Brand Example) * Amitriptyline/Perphenazine * Aripiprazole ODT; Oral Solution (Abilify®); Tablet (Abilify®)
    [Show full text]
  • Promethazine-Chlorpromazine Combination in the Treatment of Unmanageable Psychotic Patients Armando R
    Henry Ford Hospital Medical Journal Volume 17 | Number 4 Article 10 12-1969 Promethazine-Chlorpromazine Combination in the Treatment of Unmanageable Psychotic Patients Armando R. Favazza Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, Psychiatry and Psychology Commons, and the Public Health Commons Recommended Citation Favazza, Armando R. (1969) "Promethazine-Chlorpromazine Combination in the Treatment of Unmanageable Psychotic Patients," Henry Ford Hospital Medical Journal : Vol. 17 : No. 4 , 305-310. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol17/iss4/10 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Henry Ford Hosp. Med. Journal VoL 17, No. 4, 1969 Promethazine-chlorpromazine Combination in the Treatment of Unmanageable Psychotic Patients Armando R. Favazza, M.D.* Administering a combination of promethazine and chlorpromazine to patients with a "galloping psychosis" has an antipsychotic and tranquilizing effect which calms them down to a more manageable and less aggressive state. The drugs are chemically similar; promethazine's actions are strongly potentiated in the combina­ tion, so large doses must be given under careful supervision. Case histories demonstrate successful short term management of acutely psychotic, aggressive patients who were a danger to themselves and others. Acute, intense psychotic episodes common in the author's experience for can pose difficult problems for both some patients to receive massive doses the patient and those who care for him.
    [Show full text]
  • Medications to Be Avoided Or Used with Caution in Parkinson's Disease
    Medications To Be Avoided Or Used With Caution in Parkinson’s Disease This medication list is not intended to be complete and additional brand names may be found for each medication. Every patient is different and you may need to take one of these medications despite caution against it. Please discuss your particular situation with your physician and do not stop any medication that you are currently taking without first seeking advice from your physician. Most medications should be tapered off and not stopped suddenly. Although you may not be taking these medications at home, one of these medications may be introduced while hospitalized. If a hospitalization is planned, please have your neurologist contact your treating physician in the hospital to advise which medications should be avoided. Medications to be avoided or used with caution in combination with Selegiline HCL (Eldepryl®, Deprenyl®, Zelapar®), Rasagiline (Azilect®) and Safinamide (Xadago®) Medication Type Medication Name Brand Name Narcotics/Analgesics Meperidine Demerol® Tramadol Ultram® Methadone Dolophine® Propoxyphene Darvon® Antidepressants St. John’s Wort Several Brands Muscle Relaxants Cyclobenzaprine Flexeril® Cough Suppressants Dextromethorphan Robitussin® products, other brands — found as an ingredient in various cough and cold medications Decongestants/Stimulants Pseudoephedrine Sudafed® products, other Phenylephrine brands — found as an ingredient Ephedrine in various cold and allergy medications Other medications Linezolid (antibiotic) Zyvox® that inhibit Monoamine oxidase Phenelzine Nardil® Tranylcypromine Parnate® Isocarboxazid Marplan® Note: Additional medications are cautioned against in people taking Monoamine oxidase inhibitors (MAOI), including other opioids (beyond what is mentioned in the chart above), most classes of antidepressants and other stimulants (beyond what is mentioned in the chart above).
    [Show full text]
  • Perphenazine Shortage
    Perphenazine Shortage Perphenazine is currently only marketed by one company, AA Pharma Inc.1 DIN Company Brand Name Active ingredient Strength 00335096 AA PHARMA INC PERPHENAZINE PERPHENAZINE 16 MG 00335118 AA PHARMA INC PERPHENAZINE PERPHENAZINE 8 MG 00335126 AA PHARMA INC PERPHENAZINE PERPHENAZINE 4 MG 00335134 AA PHARMA INC PERPHENAZINE PERPHENAZINE 2 MG Perphenazine is a piperazine phenothiazine.2 Indications3: Psychotic disorders Nausea and vomiting Shortage management strategies: 1. Ensure medication is indicated. For example, first general antipsychotics should be avoided if possible in elderly patients.4 If no clear indication, consider tapering patient off the medication. 2. Therapeutic alternatives2,4: a) Phenothiazines are the most similar pharmacologic alternatives: CPE* Drug Psychotic Disorder: Nausea and Vomiting: (perphenazine Suggested Dose Suggested Dose = 10 mg) Initial dose: 25–75 mg daily in 2–4 divided doses. Daily dose may be ↑twice weekly by 25– 50 mg until symptoms are controlled. During an acute 12.5–25 mg Q 4–6H Chlorpromazine 100 mg episode of schizophrenia: 300– Increase dose as needed and 1000 mg/day tolerated Maintenance dose: 300–600 mg/day given in 1 or 2 divided doses with larger dose at bedtime 2.5–10 mg daily in divided doses Q6–8H Fluphenazine 2 mg Usual dose: 1–5 mg daily as a single dose Initial dose: 25–75 mg/day; use caution if starting with >100 Methotrimeprazine 70 mg mg/day Usual dose: 50–200 mg/day Divided in 1–3 doses Prochlorperazine ? 5–10 mg 3–4 times daily 2–5 mg BID or TID Trifluoperazine 5 mg Usual dose: 15–20 mg/day * Chlorpromazine 100 mg equivalent b) Other first generation antipsychotics e.g.
    [Show full text]
  • Schizoaffective Disorder?
    WHAT IS SCHIZOAFFECTIVE DISORDER? BASIC FACTS • SYMPTOMS • FAMILIES • TREATMENTS RT P SE A Mental Illness Research, Education and Clinical Center E C I D F I A C VA Desert Pacific Healthcare Network V M R E E Long Beach VA Healthcare System N T T N A E L C IL L LN A E IC S IN Education and Dissemination Unit 06/116A S R CL ESE N & ARCH, EDUCATIO 5901 E. 7th street | Long Beach, CA 90822 basic facts Schizoaffective disorder is a chronic and treatable psychiatric Causes illness. It is characterized by a combination of 1) psychotic symp- There is no simple answer to what causes schizoaffective dis- toms, such as those seen in schizophrenia and 2) mood symptoms, order because several factors play a part in the onset of the dis- such as those seen in depression or bipolar disorder. It is a psychi- order. These include a genetic or family history of schizoaffective atric disorder that can affect a person’s thinking, emotions, and be- disorder, schizophrenia, or bipolar disorder, biological factors, en- haviors and can impact all aspects of daily living, including work, vironmental stressors, and stressful life events. school, social relationships, and self-care. Research shows that the risk of schizoaffective disorder re- Schizoaffective disorder is considered a psychotic disorder sults from the influence of genes acting together with biological because of its prominent features of hallucinations and delusions. and environmental factors. A family history of schizoaffective dis- Therefore, people with this illness have periods when they have order does not necessarily mean children or other relatives will difficulty understanding the reality around them.
    [Show full text]
  • 207533Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 207533Orig1s000 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 207553 Priority or Standard Standard Submit Date(s) 8/22/2014 Received Date(s) 8/22/2014 PDUFA Goal Date 8/22/2015 Division / Office DPP/ODE1 Reviewer Name(s) Lucas Kempf, MD Review Completion Date October 2, 2015 Established Name Aripiprazole lauroxil (Proposed) Trade Name Aristada Therapeutic Class Antipsychotic Applicant Alkermes Inc. Formulation(s) Extended release injection Dosing Regimen Suspension/ IM up to 6 weeks Indication(s) Schizophrenia Intended Population(s) Schizophrenia Template Version: March 6, 2009 Reference ID: 3806701 Clinical Review Lucas Kempf, MD NDA 207533 Aristada, Aripiprazole lauroxil Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.2 Risk Benefit Assessment .................................................................................... 7 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 8 1.4 Recommendations for Postmarket Requirements and Commitments ................ 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 8 2.1 Product Information ............................................................................................ 8 2.2 Currently Available Treatments for Proposed Indications ..................................
    [Show full text]
  • Drug-Induced Parkinsonism
    InformationInformation Sheet Sheet Drug-induced Parkinsonism Terms highlighted in bold italic are defined in increases with age, hypertension, diabetes, the glossary at the end of this information sheet. atrial fibrillation, smoking and high cholesterol), because of an increased risk of stroke and What is drug-induced parkinsonism? other cerebrovascular problems. It is unclear About 7% of people with parkinsonism whether there is an increased risk of stroke with have developed their symptoms following quetiapine and clozapine. See the Parkinson’s treatment with particular medications. This UK information sheet Hallucinations and form of parkinsonism is called ‘drug-induced Parkinson’s. parkinsonism’. While these drugs are used primarily as People with idiopathic Parkinson’s disease antipsychotic agents, it is important to note and other causes of parkinsonism may also that they can be used for other non-psychiatric develop worsening symptoms if treated with uses, such as control of nausea and vomiting. such medication inadvertently. For people with Parkinson’s, other anti-sickness drugs such as domperidone (Motilium) or What drugs cause drug-induced ondansetron (Zofran) would be preferable. parkinsonism? Any drug that blocks the action of dopamine As well as neuroleptics, some other drugs (referred to as a dopamine antagonist) is likely can cause drug-induced parkinsonism. to cause parkinsonism. Drugs used to treat These include some older drugs used to treat schizophrenia and other psychotic disorders high blood pressure such as methyldopa such as behaviour disturbances in people (Aldomet); medications for dizziness and with dementia (known as neuroleptic drugs) nausea such as prochlorperazine (Stemetil); are possibly the major cause of drug-induced and metoclopromide (Maxolon), which is parkinsonism worldwide.
    [Show full text]